|
|
Previous Article | Table of Contents | Next Article 
All-trans retinoic acid as a differentiation therapy for acute
promyelocytic leukemia. I. Clinical results [see comments]
S Castaigne, C Chomienne, MT Daniel, P Ballerini, R Berger, P Fenaux and L Degos
Departement d'Hematologie, Hopital St Louis, Paris, France.
Twenty-two patients with acute promyelocytic leukemia were treated with
all-trans retinoic acid (RA, 45 mg/m2 per day) for 90 days. Of the 22, four
patients were previously untreated, two were resistant after conventional
chemotherapy, and 16 were in first (n = 11), second (n = 4), or third (n =
1) relapse. We observed 14 complete response, four transient responses, one
failure, and three early deaths. Length of hospitalization and number of
transfusions were notably reduced in complete responders. Correction of
coagulation disorders and an increase of WBCs were the first signs of
all-trans RA efficacy. Morphologic analysis performed at days 0, 15, 30,
45, 60, and 90 showed that complete remissions were obtained without bone
marrow (BM) hypoplasia. Presence of Auer rods in the maturing cells
confirmed the differentiation effect of the treatment. At remission, the
t(15;17) initially present in 20 patients was not found. The in vitro
studies showed a differentiation in the presence of all-trans RA in 16 of
the 18 tested cases. The single nonresponder to all trans RA in vitro did
not respond in vivo. Adverse effects of RA therapy--skin and mucosa
dryness, hypertriglyceridemia, and increase of hepatic transaminases-- were
frequently noted. We also observed bone pain in 11 patients and
hyperleukocytosis in four patients. Whether maintenance treatment consisted
of low-dose chemotherapy or all-trans RA, early relapses were observed.
Five patients are still in complete remission (CR) at 4 to 13 months. Our
study confirms the major efficacy of all-trans RA in M3, even in relapsing
patients. Remissions are obtained by a differentiation process.
Volume 76,
Issue 9,
pp. 1704-1709,
11/01/1990
Copyright © 1990 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y.-H. Van, W.-H. Lee, S. Ortiz, M.-H. Lee, H.-J. Qin, and C.-P. Liu
All-trans Retinoic Acid Inhibits Type 1 Diabetes by T Regulatory (Treg)-Dependent Suppression of Interferon-{gamma}-Producing T-cells Without Affecting Th17 Cells
Diabetes,
January 1, 2009;
58(1):
146 - 155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang, R. Patel, and G. P. Studzinski
hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cells
Mol. Cancer Ther.,
September 1, 2008;
7(9):
2798 - 2806.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-Y. Wang and Z. Chen
Acute promyelocytic leukemia: from highly fatal to highly curable
Blood,
March 1, 2008;
111(5):
2505 - 2515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Tallman and J. K. Altman
Curative Strategies in Acute Promyelocytic Leukemia
Hematology,
January 1, 2008;
2008(1):
391 - 399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Darmanin, J. Chen, S. Zhao, H. Cui, R. Shirkoohi, N. Kubo, Y. Kuge, N. Tamaki, K. Nakagawa, J.-i. Hamada, et al.
All-trans Retinoic Acid Enhances Murine Dendritic Cell Migration to Draining Lymph Nodes via the Balance of Matrix Metalloproteinases and Their Inhibitors
J. Immunol.,
October 1, 2007;
179(7):
4616 - 4625.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al.
Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group
J. Clin. Oncol.,
December 20, 2006;
24(36):
5703 - 5710.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich
All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients.
Cancer Res.,
September 15, 2006;
66(18):
9299 - 9307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Cimino, F. Lo-Coco, S. Fenu, L. Travaglini, E. Finolezzi, M. Mancini, M. Nanni, A. Careddu, F. Fazi, F. Padula, et al.
Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia.
Cancer Res.,
September 1, 2006;
66(17):
8903 - 8911.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Purton, S. Dworkin, G. H. Olsen, C. R. Walkley, S. A. Fabb, S. J. Collins, and P. Chambon
RAR{gamma} is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation
J. Exp. Med.,
May 15, 2006;
203(5):
1283 - 1293.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Y Liu, M. P Stokkel, A. M Pereira, E. P Corssmit, H. A Morreau, J. A Romijn, and J. W A Smit
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Eur. J. Endocrinol.,
April 1, 2006;
154(4):
525 - 531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ghavamzadeh, K. Alimoghaddam, S. H. Ghaffari, S. Rostami, M. Jahani, R. Hosseini, A. Mossavi, E. Baybordi, A. Khodabadeh, M. Iravani, et al.
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
Ann. Onc.,
January 1, 2006;
17(1):
131 - 134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Jing, N. Hellinger, L. Xia, A. Monks, E. A. Sausville, A. Zelent, and S. Waxman
Benzodithiophenes Induce Differentiation and Apoptosis in Human Leukemia Cells
Cancer Res.,
September 1, 2005;
65(17):
7847 - 7855.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Xu, F. Guidez, A. Glasow, D. Chung, K. Petrie, K. Stegmaier, K.-K. Wang, J. Zhang, Y. Jing, A. Zelent, et al.
Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor {alpha} and Enhancing Changes in all-trans-Retinoic Acid-Regulated Gene Expression
Cancer Res.,
September 1, 2005;
65(17):
7856 - 7865.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. A. Ioannidis
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
JAMA,
July 13, 2005;
294(2):
218 - 228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kumagai, L.-Y. Shih, S. V. Hughes, J. C. Desmond, J. O'Kelly, M. Hewison, and H. P. Koeffler
19-Nor-1,25(OH)2D2 (a Novel, Noncalcemic Vitamin D Analogue), Combined with Arsenic Trioxide, Has Potent Antitumor Activity against Myeloid Leukemia
Cancer Res.,
March 15, 2005;
65(6):
2488 - 2497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Heuze, F. C. Guibal, C. A. Banks, J. W. Conaway, R. C. Conaway, Y. E. Cayre, A. Benecke, and P. G. Lutz
ASB2 Is an Elongin BC-interacting Protein That Can Assemble with Cullin 5 and Rbx1 to Reconstitute an E3 Ubiquitin Ligase Complex
J. Biol. Chem.,
February 18, 2005;
280(7):
5468 - 5474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells
Blood,
February 15, 2005;
105(4):
1669 - 1677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. de Botton, A. Fawaz, S. Chevret, H. Dombret, X. Thomas, M. Sanz, A. Guerci, J. San Miguel, J. de la Serna, A.M. Stoppa, et al.
Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-Trans-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group
J. Clin. Oncol.,
January 1, 2005;
23(1):
120 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Cote, S. McNamara, D. Brambilla, A. Bianchini, G. Rizzo, S. V. del Rincon, F. Grignani, C. Nervi, and W. H. Miller Jr
Expression of SMRT{beta} promotes ligand-induced activation of mutated and wild-type retinoid receptors
Blood,
December 15, 2004;
104(13):
4226 - 4235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Konopleva, E. Elstner, T. J. McQueen, T. Tsao, A. Sudarikov, W. Hu, W. D. Schober, R.-Y. Wang, D. Chism, S. M. Kornblau, et al.
Peroxisome proliferator-activated receptor {gamma} and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias
Mol. Cancer Ther.,
October 1, 2004;
3(10):
1249 - 1262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Battistella, L. D Burry, and J. T Seki
Retinoic acid syndrome after one dose of all-transretinoic acid
Journal of Oncology Pharmacy Practice,
September 1, 2004;
10(3):
149 - 154.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Prisco, A. Maiorana, C. Guerzoni, G. Calin, B. Calabretta, R. Voit, I. Grummt, and R. Baserga
Role of Pescadillo and Upstream Binding Factor in the Proliferation and Differentiation of Murine Myeloid Cells
Mol. Cell. Biol.,
June 15, 2004;
24(12):
5421 - 5433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Davison, K. K. Mann, S. Waxman, and W. H. Miller Jr
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells
Blood,
May 1, 2004;
103(9):
3496 - 3502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Pitha-Rowe, B. A. Hassel, and E. Dmitrovsky
Involvement of UBE1L in ISG15 Conjugation during Retinoid-induced Differentiation of Acute Promyelocytic Leukemia
J. Biol. Chem.,
April 30, 2004;
279(18):
18178 - 18187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. de Botton, V. Coiteux, S. Chevret, C. Rayon, E. Vilmer, M. Sanz, J. de La Serna, N. Philippe, A. Baruchel, G. Leverger, et al.
Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and Chemotherapy
J. Clin. Oncol.,
April 15, 2004;
22(8):
1404 - 1412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-X. Shen, Z.-Z. Shi, J. Fang, B.-W. Gu, J.-M. Li, Y.-M. Zhu, J.-Y. Shi, P.-Z. Zheng, H. Yan, Y.-F. Liu, et al.
Inaugural Article: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
PNAS,
April 13, 2004;
101(15):
5328 - 5335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, M. I. Dawson, Y. Ning, L. Polin, R. E. Parchment, T. Corbett, A. N. Mohamed, K.-C. Feng, L. Farhana, A. K. Rishi, et al.
Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog
Blood,
November 15, 2003;
102(10):
3743 - 3752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Moog-Lutz, F. Cave-Riant, F. C. Guibal, M. A. Breau, Y. Di Gioia, P. O. Couraud, Y. E. Cayre, S. Bourdoulous, and P. G. Lutz
JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells
Blood,
November 1, 2003;
102(9):
3371 - 3378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Barbey, J. C. Pezzullo, and S. L. Soignet
Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies
J. Clin. Oncol.,
October 1, 2003;
21(19):
3609 - 3615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kambhampati, Y. Li, A. Verma, A. Sassano, B. Majchrzak, D. K. Deb, S. Parmar, N. Giafis, D. V. Kalvakolanu, A. Rahman, et al.
Activation of Protein Kinase C{delta} by All-trans-retinoic Acid
J. Biol. Chem.,
August 29, 2003;
278(35):
32544 - 32551.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kusmartsev, F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich
All-trans-Retinoic Acid Eliminates Immature Myeloid Cells from Tumor-bearing Mice and Improves the Effect of Vaccination
Cancer Res.,
August 1, 2003;
63(15):
4441 - 4449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Raffoux, P. Rousselot, J. Poupon, M.-T. Daniel, B. Cassinat, R. Delarue, A.-L. Taksin, D. Rea, A. Buzyn, A. Tibi, et al.
Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia
J. Clin. Oncol.,
June 15, 2003;
21(12):
2326 - 2334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-y. Wang
Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis
Hematology,
January 1, 2003;
2003(1):
1 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Livny, I. Kaplan, R. Reifen, S. Polak-Charcon, Z. Madar, and B. Schwartz
Lycopene Inhibits Proliferation and Enhances Gap-Junction Communication of KB-1 Human Oral Tumor Cells
J. Nutr.,
December 1, 2002;
132(12):
3754 - 3759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Cote, A. Rosenauer, A. Bianchini, K. Seiter, J. Vandewiele, C. Nervi, and W. H. Miller Jr
Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells
Blood,
September 18, 2002;
100(7):
2586 - 2596.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.-P. Lu, J.-Y. Qiu, B. Jiang, Q. Wang, K.-Y. Liu, Y.-R. Liu, and S.-S. Chen
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report
Blood,
May 1, 2002;
99(9):
3136 - 3143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield
Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide
Oncologist,
April 1, 2002;
7(90001):
1 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe
Acute promyelocytic leukemia: evolving therapeutic strategies
Blood,
February 1, 2002;
99(3):
759 - 767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. C. Guibal, C. Moog-Lutz, P. Smolewski, Y. Di Gioia, Z. Darzynkiewicz, P. G. Lutz, and Y. E. Cayre
ASB-2 Inhibits Growth and Promotes Commitment in Myeloid Leukemia Cells
J. Biol. Chem.,
January 4, 2002;
277(1):
218 - 224.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Tamagawa, K. Shimizu, T. Ebine, Y. Maitani, T. Fukui, K.-i. Kawai, and N. Takahashi
Antitumor Efficacy in Vitro and in Vivo of Falconensones, a New Type of Polyene
Clin. Cancer Res.,
November 1, 2001;
7(11):
3551 - 3558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Jurcic, S. D. Nimer, D. A. Scheinberg, T. DeBlasio, R. P. Warrell Jr, and W. H. Miller Jr
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia | |